Evaluation of Immunogenicity : Malaria Subunit Vaccine

免疫原性评价：疟疾亚单位疫苗

• 批准号: 6443267
• 负责人: DAVID E CLEMENTS
• 金额: $ 12.99万
• 依托单位: HAWAII BIOTECH, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-06-15 至 2003-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6443267
• 关键词: active immunization; immunomodulators; laboratory mouse; laboratory rabbit; malaria vaccines; protein engineering; protozoal antigen; surface antigens; tissue /cell culture; vaccine development; vector vaccine

Malaria is a tropical parasitic disease that poses a significant health threat to much of the world. Each year, approximately 500 million become infected and more them 2 million die. There is great need to control the spread of the disease. One of the main focuses of malaria vaccine development has been on the use of recombinant proteins derived from the various developmental stages of the parasite. The goal of the proposed research is to enhance the immune response to MSP-1C- terminal subunits. Several clinically relevant adjuvants will be evaluated for the ability to elicit an appropriate immune response when combined with an MSP-1 p42 subunit. Additionally, the p42 subunit will be reengineered to contain conserved T-cell epitopes in an effort to focus the antibody response to the conserved p19 region. The ability to identify adjuvant formations that can potentiate an effective immune response to the MSP-1 p42 antigen and/or the ability to enhance the immune response to p19 by improved subunit design would facilitate the development of MSP-1 C-terminal subunits into viable malaria vaccine products. PROPOSED COMMERCIAL APPLICATIONS: Malaria poses a significant world-wide health threat. Currently, there is no vaccine for malaria. The proposed research is focused on the improvement of malaria subunit vaccines. The ability to identify suitable clinically relevant adjuvants for the MSP-1p42 subunit and/or enhance the immunogenicity of the p42 subunit by focusing T-cell help would contribute to the development of an effective malaria subunit vaccine.

疟疾是一种热带寄生虫病，对世界大部分地区造成严重的健康威胁。每年约有 5 亿人被感染，其中 200 万人死亡。非常需要控制疾病的传播。疟疾疫苗开发的主要焦点之一是使用源自寄生虫各个发育阶段的重组蛋白。 本研究的目标是增强对 MSP-1C 末端亚基的免疫反应。将评估几种临床相关佐剂与 MSP-1 p42 亚基组合时引发适当免疫反应的能力。此外，p42 亚基将被重新设计以包含保守的 T 细胞表位，以便将抗体反应集中在保守的 p19 区域。识别可增强对 MSP-1 p42 抗原的有效免疫应答的佐剂形成的能力和/或通过改进亚基设计增强对 p19 免疫应答的能力将有助于将 MSP-1 C 末端亚基开发为可行的疟疾疫苗产品。拟议的商业应用：疟疾对全球健康构成重大威胁。目前，还没有针对疟疾的疫苗。拟议的研究重点是疟疾亚单位疫苗的改进。为 MSP-1p42 亚基识别合适的临床相关佐剂和/或通过集中 T 细胞帮助增强 p42 亚基的免疫原性的能力将有助于开发有效的疟疾亚基疫苗。